Loading...
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Mutations of the type III receptor tyrosine kinase FLT3 occur in approximately 30% of acute myeloid leukemia patients and lead to constitutive activation. This has made FLT3-activating mutations an attractive drug target because they are probable driver mutations of this disease. As more potent FLT3...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3879910/ https://ncbi.nlm.nih.gov/pubmed/24227820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-10-529313 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|